Clinical Trials Browser

Phase 2 × Immunoglobulin Light-chain Amyloidosis × dexamethasone 21-phosphate × Clear all

NCT00520767 2023-12-22

Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

Phase 2 Completed

35 enrolled 7 charts

Immunoglobulin Light-chain Amyloidosis

NCT03252600 2023-01-25

Lenalidomide, Dexamethasone, and Elotuzumab With or Without Cyclophosphamide in Treating Patients With Relapsed Primary Amyloidosis

Phase 2 Unknown

Immunoglobulin Light-chain Amyloidosis